Ling He | Cardiotoxicity | Best Research Article Award

Posted on by Pencis

Assoc. Prof. Dr. Ling He | Cardiotoxicity | Best Research Article Award

Assoc. Prof. Dr. Ling He, The Second Affiliated Hospital of Nanchang University, China

Assoc. Prof. Dr. Ling He is a distinguished medical professional at The Second Affiliated Hospital of Nanchang University, China. With a strong background in clinical medicine, she specializes in translational research, innovative diagnostics, and patient-centered care. As an associate professor, she actively mentors medical students and leads research projects focused on improving clinical outcomes and healthcare quality. Her work has been published in reputed journals and widely cited, reflecting her influence in the medical research community. Dr. He remains committed to advancing healthcare practices through academic excellence, collaborative research, and continuous medical innovation.

AUTHOR PROFILE

Scopus Profile

🧠 EARLY ACADEMIC PURSUITS:

Assoc. Prof. Dr. Ling He began her academic journey with a strong foundation in medical sciences, developing an early interest in clinical medicine and healthcare research. She pursued her undergraduate and postgraduate studies in prestigious medical institutions in China, eventually specializing in fields aligned with clinical diagnosis, treatment innovation, and patient-centric research. Her commitment to academic excellence and scientific rigor laid the groundwork for a promising career in medical academia and clinical research.

🩺 PROFESSIONAL ENDEAVORS:

Dr. Ling He currently serves as an Associate Professor at The Second Affiliated Hospital of Nanchang University, one of China’s reputed medical research and teaching hospitals. In her role, she is deeply involved in clinical practice, academic instruction, and mentoring young medical professionals. Her position also includes collaboration with multidisciplinary teams to improve healthcare delivery and treatment outcomes. Over the years, she has participated in numerous research projects, contributing both as a principal investigator and a collaborator.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOTOXICITY:

Dr. Ling He’s research spans a range of clinical and biomedical sciences, focusing on:

  • Translational medicine

  • Clinical treatment protocols and their effectiveness

  • Patient safety and quality improvement in hospitals

  • Innovative diagnostic techniques

  • Public health and epidemiological studies

Her studies aim to bridge the gap between laboratory research and bedside application, ensuring that the latest scientific discoveries translate into real-world clinical improvements.

🌍 IMPACT AND INFLUENCE:

Dr. Ling He has significantly influenced both her peers and students through her mentorship, research guidance, and active involvement in academic societies. Her work has contributed to:

  • Improved clinical outcomes

  • Refined patient management protocols

  • Enhanced medical education at Nanchang University

She is frequently invited to speak at conferences and seminars, where she shares her expertise on current medical challenges and innovations. Her contributions have also helped raise the global profile of The Second Affiliated Hospital of Nanchang University in academic circles.

📚 ACADEMIC CITES:

Dr. He’s research papers have been published in national and international journals, many of which are indexed in Scopus, Web of Science, and PubMed. Her work is often cited by researchers in:

  • Clinical medicine

  • Nursing

  • Hospital management

  • Public health

This scholarly attention showcases her relevance and credibility in the academic and clinical research community.

🌟 LEGACY AND FUTURE CONTRIBUTIONS:

Assoc. Prof. Dr. Ling He is building a legacy as a thought leader in clinical medicine and hospital practice. Her future goals include:

  • Expanding international collaborations

  • Developing new models of patient-centered care

  • Training the next generation of clinicians and researchers

  • Publishing high-impact research in global medical journals

Her ongoing work is expected to shape healthcare policy, influence clinical education reforms, and enhance patient care standards both in China and beyond.

📝 OTHER IMPORTANT HIGHLIGHTS:

  • Active educator and mentor in Nanchang University’s clinical programs

  • Collaborative contributor to multi-hospital research networks

  • Advocate for innovation in healthcare systems

  • Works at the intersection of clinical practice and academic research

🌐CONCLUSION:

Assoc. Prof. Dr. Ling He stands as a dedicated and influential figure in clinical medicine and academic research. Through her role at The Second Affiliated Hospital of Nanchang University, she continues to bridge the gap between research and practice, contributing significantly to patient care and medical education. Her passion for innovation, mentorship, and collaboration is shaping the future of healthcare in China and beyond. As she advances in her career, Dr. He remains a beacon of inspiration for young professionals and a catalyst for positive change in the medical community.

TOP NOTABLE PUBLICATION

Joint assessment of abdominal obesity and non-traditional lipid parameters for primary prevention of cardiometabolic multimorbidity: insights from the China health and retirement longitudinal study 2011–2018

Authors: H. Lai, Y. Tu, C. Liao, L. He, J. Li

Journal: Cardiovascular Diabetology

Year: 2025

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Pencis

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012